SCHEMBL21568084

SCHEMBL21568084

N#Cc1ccc(NC(=O)Nc2nc3ccc(Cl)cc3s2)cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 11/20 0.60
▸ MEN1 O00255 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ HPGD P15428 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ BLM P54132 1/20 0.56
▸ KDM4E B2RXH2 2/20 0.55
▸ RECQL P46063 1/20 0.55
▸ DYRK1A Q13627 1/20 0.55
▸ FSCN1 Q16658 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ ATM Q13315 1/20 0.53
▸ CASP3 P42574 2/20 0.52
▸ SENP8 Q96LD8 2/20 0.52
▸ SENP7 Q9BQF6 2/20 0.52
▸ SENP6 Q9GZR1 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21569108 0.92 KDM4E (0.56) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568063 0.91 HSD17B10 (0.57) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568179 0.89 KDM4E (0.53) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568083 0.89 KDM4E (0.56) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568250 0.88 BLM (0.55) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568161 0.88 KDM4E (0.57) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568967 0.87 BLM (0.54) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568183 0.87 CSNK1D (0.62) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568078 0.87 HSD17B10 (0.57) HSD17B10MEN1KMT2AHPGDSMN1; SMN2
SCHEMBL21568257 0.85 KDM4E (0.61) HSD17B10MEN1KMT2AKDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 — — US disclosed
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2021-04-22 — — US disclosed
WO-2019217509-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2019-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 HSD17B10 4412/4885MEN1 977/4885KMT2A 623/4885
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER VHL, TP53, NUDT1 HSD17B10 4512/4885MEN1 1079/4885KMT2A 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback